ABEONA THERAPEUTICS INC. Net Income (Loss) Available to Common Stockholders, Basic
ABEONA THERAPEUTICS INC. (ABEO) reported Net Income (Loss) Available to Common Stockholders, Basic of -$12.00 million for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-15.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2025-05-15
- ABEONA THERAPEUTICS INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-03-31 was -$12.00M.
- ABEONA THERAPEUTICS INC. net income (loss) available to common stockholders, basic for the quarter ending 2024-12-31 was -$9.30M.
- ABEONA THERAPEUTICS INC. net income (loss) available to common stockholders, basic for the quarter ending 2024-09-30 was -$30.20M.
- ABEONA THERAPEUTICS INC. net income (loss) available to common stockholders, basic for the quarter ending 2024-06-30 was $7.40M.
- ABEONA THERAPEUTICS INC. net income (loss) available to common stockholders, basic for fiscal 2024 was -$63.70M.
- ABEONA THERAPEUTICS INC. net income (loss) available to common stockholders, basic for fiscal 2023 was -$54.20M.
- ABEONA THERAPEUTICS INC. net income (loss) available to common stockholders, basic for fiscal 2022 was -$43.48M.
- ABEONA THERAPEUTICS INC. net income (loss) available to common stockholders, basic for fiscal 2021 was -$84.94M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 12 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | -$12.00M 10-Q · filed 2025-05-15 | -$21.30M derived: sum of 2 quarters · filed 2025-05-15 | -$51.50M derived: sum of 3 quarters · filed 2025-05-15 | -$44.10M derived: sum of 4 quarters · filed 2025-05-15 | ||||
| 2024-12-31 | -$9.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$39.50M derived: sum of 2 quarters · filed 2025-03-20 | -$32.10M derived: sum of 3 quarters · filed 2025-03-20 | -$63.70M 10-K · filed 2025-03-20 | ||||
| 2024-09-30 | -$30.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$22.80M derived: sum of 2 quarters · filed 2024-11-14 | -$54.40M 10-Q · filed 2024-11-14 | -$71.00M derived: sum of 4 quarters · filed 2025-05-15 | ||||
| 2024-06-30 | $7.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$24.20M 10-Q · filed 2024-08-12 | -$40.80M derived: sum of 3 quarters · filed 2025-05-15 | -$52.64M derived: sum of 4 quarters · filed 2025-05-15 | ||||
| 2024-03-31 | -$31.60M 10-Q · filed 2025-05-15 | -$48.20M derived: sum of 2 quarters · filed 2025-05-15 | -$60.04M derived: sum of 3 quarters · filed 2025-05-15 | -$76.69M derived: sum of 4 quarters · filed 2025-05-15 | ||||
| 2023-12-31 | -$16.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$28.44M derived: sum of 2 quarters · filed 2025-03-20 | -$45.09M derived: sum of 3 quarters · filed 2025-03-20 | -$54.20M 10-K · filed 2025-03-20 | -$54.19M 10-K · filed 2024-03-18 | |||
| 2023-09-30 | -$11.84M 10-Q · filed 2023-11-13 | -$28.49M derived: sum of 2 quarters · filed 2023-11-13 | -$37.60M 10-Q · filed 2024-11-14 | -$37.60M 10-Q · filed 2023-11-13 | -$44.71M derived: sum of 4 quarters · filed 2024-05-15 | |||
| 2023-06-30 | -$16.65M 10-Q · filed 2023-08-08 | -$25.80M 10-Q · filed 2024-08-12 | -$25.76M 10-Q · filed 2023-08-08 | -$32.88M derived: sum of 3 quarters · filed 2024-05-15 | -$39.31M derived: sum of 4 quarters · filed 2024-05-15 | |||
| 2023-03-31 | -$9.10M 10-Q · filed 2024-05-15 | -$16.22M derived: sum of 2 quarters · filed 2024-05-15 | -$22.66M derived: sum of 3 quarters · filed 2024-05-15 | -$30.53M derived: sum of 4 quarters · filed 2024-05-15 | ||||
| 2022-12-31 | -$7.12M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | -$13.55M derived: sum of 2 quarters · filed 2024-03-18 | -$21.43M derived: sum of 3 quarters · filed 2024-03-18 | -$43.48M 10-K · filed 2024-03-18 | ||||
| 2022-09-30 | -$6.43M 10-Q · filed 2023-11-13 | -$9.48M 10-Q · filed 2022-11-14 | -$14.31M derived: sum of 2 quarters · filed 2023-11-13 | -$36.36M 10-Q · filed 2023-11-13 | -$42.35M 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | -$7.88M 10-Q · filed 2023-08-08 | -$12.08M 10-Q · filed 2022-08-11 | -$29.92M 10-Q · filed 2023-08-08 | -$32.87M 10-Q · filed 2022-08-11 | ||||
| 2021-12-31 | -$46.68M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$53.73M derived: sum of 2 quarters · filed 2023-03-29 | -$68.93M derived: sum of 3 quarters · filed 2023-03-29 | -$84.94M 10-K · filed 2023-03-29 | ||||
| 2021-09-30 | -$7.04M 10-Q · filed 2022-11-14 | -$22.25M derived: sum of 2 quarters · filed 2022-11-14 | -$38.25M 10-Q · filed 2022-11-14 | |||||
| 2021-06-30 | -$15.21M 10-Q · filed 2022-08-11 | -$31.21M 10-Q · filed 2022-08-11 | ||||||
| 2016-12-31 | -$21.87M 10-K · filed 2017-03-30 | |||||||
| 2015-12-31 | -$2.34M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-30 | -$8.41M derived: sum of 2 quarters · filed 2017-03-30 | -$12.53M derived: sum of 3 quarters · filed 2017-03-30 | -$14.53M 10-K · filed 2017-03-30 | ||||
| 2015-09-30 | -$6.07M 10-Q · filed 2015-11-16 | -$10.19M derived: sum of 2 quarters · filed 2015-11-16 | -$12.19M 10-Q · filed 2015-11-16 | -$24.81M derived: sum of 4 quarters · filed 2016-03-30 | ||||
| 2015-06-30 | -$4.11M 10-Q · filed 2015-08-14 | -$6.11M 10-Q · filed 2015-08-14 | -$18.74M derived: sum of 3 quarters · filed 2016-03-30 | -$20.95M derived: sum of 4 quarters · filed 2016-03-30 | ||||
| 2015-03-31 | -$2.00M 10-Q · filed 2015-05-14 | -$14.63M derived: sum of 2 quarters · filed 2016-03-30 | -$16.84M derived: sum of 3 quarters · filed 2016-03-30 | -$30.07M derived: sum of 4 quarters · filed 2016-03-30 | ||||
| 2014-12-31 | -$12.63M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | -$14.84M derived: sum of 2 quarters · filed 2016-03-30 | -$28.07M derived: sum of 3 quarters · filed 2016-03-30 | -$29.65M 10-K · filed 2016-03-30 | ||||
| 2014-09-30 | -$2.21M 10-Q · filed 2015-11-16 | -$15.44M derived: sum of 2 quarters · filed 2015-11-16 | -$17.03M 10-Q · filed 2015-11-16 | -$18.80M derived: sum of 4 quarters · filed 2015-11-16 | ||||
| 2014-06-30 | -$13.23M 10-Q · filed 2015-08-14 | -$14.82M 10-Q · filed 2015-08-14 | -$16.59M derived: sum of 3 quarters · filed 2015-08-14 | -$17.49M derived: sum of 4 quarters · filed 2015-08-14 | ||||
| 2014-03-31 | -$1.58M 10-Q · filed 2015-05-14 | -$853.00K 10-Q · filed 2014-05-12 | -$3.35M derived: sum of 2 quarters · filed 2015-05-14 | -$4.25M derived: sum of 3 quarters · filed 2015-05-14 | -$3.39M derived: sum of 4 quarters · filed 2015-05-14 | |||
| 2013-12-31 | -$1.77M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-31 | -$2.67M derived: sum of 2 quarters · filed 2015-03-31 | -$1.80M derived: sum of 3 quarters · filed 2015-03-31 | $1.55M 10-K · filed 2015-03-31 | ||||
| 2013-09-30 | -$899.00K 10-Q · filed 2014-11-14 | -$32.00K derived: sum of 2 quarters · filed 2014-11-14 | $3.32M 10-Q · filed 2014-11-14 | $22.47M derived: sum of 4 quarters · filed 2014-11-14 | ||||
| 2013-06-30 | $867.00K 10-Q · filed 2014-08-14 | $4.22M 10-Q · filed 2014-08-14 | $23.37M derived: sum of 3 quarters · filed 2014-08-14 | $8.06M derived: sum of 4 quarters · filed 2014-08-14 | ||||
| 2013-03-31 | $3.35M 10-Q · filed 2014-05-12 | $22.50M derived: sum of 2 quarters · filed 2014-05-12 | $7.19M derived: sum of 3 quarters · filed 2014-05-12 | -$3.85M derived: sum of 4 quarters · filed 2014-05-12 | ||||
| 2012-12-31 | $19.15M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-26 | $3.84M derived: sum of 2 quarters · filed 2014-03-26 | -$7.20M derived: sum of 3 quarters · filed 2014-03-26 | -$12.53M 10-K · filed 2014-03-26 | ||||
| 2012-09-30 | -$15.31M 10-Q · filed 2013-11-14 | -$26.35M derived: sum of 2 quarters · filed 2013-11-14 | -$31.68M 10-Q · filed 2013-11-14 | -$31.85M derived: sum of 4 quarters · filed 2013-11-14 | ||||
| 2012-06-30 | -$11.04M 10-Q · filed 2013-08-14 | -$16.37M 10-Q · filed 2013-08-14 | -$16.54M derived: sum of 3 quarters · filed 2013-08-14 | -$16.63M derived: sum of 4 quarters · filed 2013-08-14 | ||||
| 2012-03-31 | -$5.33M 10-Q · filed 2013-05-15 | -$5.50M derived: sum of 2 quarters · filed 2013-05-15 | -$5.59M derived: sum of 3 quarters · filed 2013-05-15 | -$7.30M derived: sum of 4 quarters · filed 2013-05-15 | ||||
| 2011-12-31 | -$166.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-20 | -$263.00K derived: sum of 2 quarters · filed 2013-03-20 | -$1.97M derived: sum of 3 quarters · filed 2013-03-20 | -$4.31M 10-K · filed 2013-03-20 | ||||
| 2011-09-30 | -$97.00K 10-Q · filed 2012-11-14 | -$1.80M derived: sum of 2 quarters · filed 2012-11-14 | -$4.14M 10-Q · filed 2012-11-14 | -$2.29M derived: sum of 4 quarters · filed 2012-11-14 | ||||
| 2011-06-30 | -$1.71M 10-Q · filed 2011-08-15 | -$4.04M 10-Q · filed 2012-08-14 | -$2.19M derived: sum of 3 quarters · filed 2012-08-14 | -$15.36M derived: sum of 4 quarters · filed 2012-08-14 | ||||
| 2011-03-31 | -$2.34M 10-Q · filed 2012-05-15 | -$485.00K derived: sum of 2 quarters · filed 2012-05-15 | -$13.66M derived: sum of 3 quarters · filed 2012-05-15 | -$12.31M derived: sum of 4 quarters · filed 2012-05-15 | ||||
| 2010-12-31 | $1.85M derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-23 | -$11.32M derived: sum of 2 quarters · filed 2012-03-23 | -$9.97M derived: sum of 3 quarters · filed 2012-03-23 | -$9.33M 10-K · filed 2012-03-23 | ||||
| 2010-09-30 | -$13.17M 10-Q · filed 2011-11-14 | -$11.83M derived: sum of 2 quarters · filed 2011-11-14 | -$11.18M 10-Q · filed 2011-11-14 | |||||
| 2010-06-30 | $1.34M 10-Q · filed 2011-08-15 | $1.99M 10-Q · filed 2011-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |